Musculoskeletal disorders are a primary cause of disability worldwide, especially in aging societies like Japan. As individuals age, reductions in muscle mass and physical activity weaken the body's ...

Up to three years of Evrysdi treatment appears safe and may help presymptomatic children with SMA reach and maintain key milestones.

Simple field-based tests of muscle strength can provide early clues about the risk of developing several long-term illnesses.

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

SMA mutations disrupt spinal cord development, with fewer nerve cells in early stages. SMN protein deficiency leads to a mesodermal fate bias, with fewer motor neurons. Increasing SOX2 pathway ...

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical ...

SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...

Oral Presentation: Del-zota Treatment is Associated with Near Normalization of CK Levels and Improvements in Key Functional Outcomes at 1 Year in Participants with DMD44 (March 11, 2026: 12:30 p.m. – ...

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first ...